New approaches to the treatment of opioid-induced constipation

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue SUPPL. 1, 2008, Pages 119-127

  Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alvimopan; Constipation; Enteric nervous system; Methylnaltrexone; Naloxone; Opioid peptides; Opioid induced bowel dysfunction; Peripherally restricted opioid receptor antagonists; Prokinetic effects

Indexed keywords

17 METHYLNALOXONE; 17 METHYLNALTREXONE; ALVIMOPAN; FENTANYL; LAXATIVE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALMEFENE GLUCURONIDE; NALOXONE; NALOXONE 3 GLUCURONIDE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE ANTAGONIST; OPIATE RECEPTOR; OXYCODONE; PLACEBO; PROKINETIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROPATHY; EVIDENCE BASED MEDICINE; FLUSHING; GASTROESOPHAGEAL REFLUX; HUMAN; ILEUS; INTESTINE FUNCTION DISORDER; INTESTINE INNERVATION; INTESTINE TRANSIT TIME; LIQUID FECES; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHARMACODYNAMICS; POSTOPERATIVE PAIN; SEDATION; SIDE EFFECT; URINE RETENTION; VOMITING;

ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; STIMULATION, CHEMICAL;

EID: 53249113782     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. MEISSNER W, SCHMIDT U, HARTMANN M, KATH R, REINHART K. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84: 105-109.
2. KURZ A, SESSLER DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-671.
3. HERBERT MK, HOLZER P. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients - current status and future options. Clin Nutr 2008; 27: 25-41.
4. KROMER W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 1988; 40: 121-162.
5. DE LUCA A, COUPAR IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 103-115.
6. HOLZER P. Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004; 361: 192-195.
7. SANGER GJ, TULADHAR BR. The role of endogenous opiates in the control of gastrointestinal motility: Predictions from in vitro modelling. Neurogastroenterol Motil 2004; 16(Suppl 2): 38-45.
8. HOLZER P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007; 16: 181-194.
9. MANARA L, BIANCHETTI A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985; 25: 249-273.
10. HOLZER P, SCHICHO R, HOLZER-PETSCHE U, LIPPE IT. The gut as a neurological organ. Wien Klin Wochenschr 2001; 113: 647-660.
11. BROOKES SJH. Classes of enteric nerve cells in the guinea-pig small intestine. Anat Rec 2001; 262: 58-70.
12. FURNESS JB. The Enteric Nervous System. Oxford: Blackwell (2006).
13. STERNINI C, PATIERNO S, SELMER IS, KIRCHGESSNER A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004; 16(Suppl 2): 3-16.
14. WOOD JD, GALLIGAN JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16(Suppl 2): 17-28.
15. LENARD L, HALMAI V, BARTHÓ L. Morphine contracts the guinea pig ileal circular muscle by interfering with a nitric oxide mediated tonic inhibition. Digestion 1999; 60: 562-566.
16. BEUBLER E, LEMBECK F. Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists. Naunyn-Schmiedeberg's Arch Pharmacol 1979; 306: 113-118.
17. TURNBERG LA. Antisecretory activity of opiates in vitro and in vivo in man. Scand J Gastroenterol 1983; 84: 79-83.
18. SHAHBAZIAN A, HEINEMANN A, SCHMIDHAMMER H, BEUBLER E, HOLZER-PETSCHE U, HOLZER P. Involvement of μ- and κ-, but not δ-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 2002; 135: 741-750.
19. BIANCHI G, FERRETTI P, RECCHIA M, ROCCHETTI M, TAVANI A, MANARA L. Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut. Gastroenterology 1983; 85: 852-858.
20. HERNDON CM, JACKSON KC, HALLIN PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002; 22: 240-250.
21. ALLAN L, HAYS H, JENSEN NH, DE WAROUX BI, BOLT M, DONALD R, KALSO E . Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001; 322: 1154-1158.
22. DEHAVEN-HUDKINS DL, DEHAVEN RN, LITTLE PJ, TECHNER LM. The involvement of the μ-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor. Pharmacol Ther 2008; 117: 162-187.
23. BECKER G, GALANDI D, BLUM HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage 2007; 34: 547-565.
24. GREENWOOD-VAN MEERVELD B, GARDNER CJ, LITTLE PJ, HICKS GA, DEHAVEN-HUDKINS DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004; 16(Suppl 2): 46-53.
25. JURNA I, KAISER R, KRETZ O, BALDAUF J. Oral naloxone reduces constipation but not antinociception from oral morphine in the rat. Neurosci Lett 1992; 142: 62-64.
26. SYKES NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-144.
27. LIU M, WITTBRODT E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48-53.
28. MÜLLER-LISSNER S, LEYENDECKER P, RUCKES MC, FLEISCHER W, REIMER K . Oral prolonged release (pr) oxycodone/naloxone combination reduces opioid-induced bowel dysfunction (OIBD). Eur J Pain 2007; 11 (Suppl 1): S82.
29. SIMPKINS JW, SMULKOWSKI M, DIXON R, TUTTLE R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988; 244: 195-205.
30. REBER P, BRENNEISEN R, FLOGERZI B, BATISTA C, NETZER P, SCHEURER U . Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine. Dig Dis Sci 2007; 52: 502-507.
31. CHESKIN LJ, CHAMI TN, JOHNSON RE, JAFFE JH. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend 1995; 39: 151-154.
32. RUSSELL J, BASS P, GOLDBERG LI, SCHUSTER CR, MERZ H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982; 78: 255-261.
33. BEATTIE DT, CHERUVU M, MAI N, O'KEEFE M, JOHNSON-RABIDOUX S, PETERSON C, KAUFMAN E, VICKERY R. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn-Schmiedeberg's Arch Pharmacol 2007; 375: 205-220.
34. YUAN CS, ISRAEL RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin. Investig. Drug 2006; 15: 541-552.
35. REICHLE FM, CONZEN PF. Methylnaltrexone, a new peripheral μ-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. Curr Opin Investig Drugs 2008; 9: 90-100.
36. KOTAKE AN, KUWAHARA SK, BURTON E, MCCOY CE, GOLDBERG LI. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 1989; 19: 1247-1254.
37. YUAN CS, DOSHAN H, CHARNEY MR, O'CONNOR M, KARRISON T, MALECKAR SA, ISRAEL RJ, MOSS J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005; 45: 538-546.
38. ROSOW CE, GOMERY P, CHEN TY, STEFANOVICH P, STAMBLER N, ISRAEL R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 2007; doi: 10.1038/ sj.cipt.6100164.
39. YUAN CS, FOSS JF, O'CONNOR M, OSINSKI J, KARRISON T, MOSS J, ROIZEN MF. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized, controlled trial. JAMA 2000; 283: 367-372.
40. SCHMIDT J, STOFFELS B, NAZIR A, DEHAVEN-HUDKINS DL, BAUER AJ. Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus. Neurogastroenterol Motil 2008; 20: 689-699.
41. FUKUDA H, SUENAGA K, TSUCHIDA D, MANTYH CR, PAPPAS TN, HICKS GA, DEHAVEN-HUDKINS DL, TAKAHASHI T. The selective μ opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. Brain Res 2006; 1102: 63-70.
42. SCHMIDT WK. Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001; 182(Suppl): 27S-38S.
43. CAMILLERI M. Alvimopan, a selective peripherally acting μ-opioid antagonist. Neurogastroenterol. Motil 2004; 17: 157-65
44. NEARY P, DELANEY CR. Alvimopan. Expert Opin Investig Drugs 2005; 14: 479-488.
45. GONENNE J, CAMILLERI M, FERBER I, BURTON D, BAXTER K, KEYASHIAN K, FOSS J, WALLIN B, DU W, ZINSMEISTER AR. Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784-791.
46. PAULSON DM, KENNEDY DT, DONOVICK RA, CARPENTER RL, CHERUBINI M, TECHNER L, DU W, MA Y, SCHMIDT WK, WALLIN B, JACKSON D. Alvimopan: An oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184-192.
47. WEBSTER L, JANSEN JP, PEPPIN J, LASKO B, IRVING G, MORLION B, SNID0W J, PIERCE A, MORTENSEN E, KLEOUDIS C, CARTER E. Alvimopan, a peripherally acting μ-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008; in press.
48. TAN EK, CORNISH J, DARZI AW, TEKKIS PP. Meta-analysis: Alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther 2007; 25: 47-57.
49. DELANEY CP, WOLFF BG, VISCUSI ER, SENAGORE AJ, FORT JG, DU W, TECHNER L, WALLIN B. Alvimopan, for postoperative ileus following bowel resection: A pooled analysis of phase III studies. Ann Surg 2007; 245: 355-363.
50. FOSS JF, FISHER DM, SCHMITH VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther 2007; doi: 10.1038/sj.clpt.6100292.
51. PUIG MM, POL O. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J Pharmacol Exp Ther 1998; 287: 1068-1075.
52. POL O, ALAMEDA F, PUIG MM. Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol Pharmacol 2001; 60: 894-899.
53. YOSHIDA S, OHTA J, YAMASAKI K, KAMEI H, HARADA Y, YAHARA T, KAIBARA A, OZAKI K, TAJIRI T, SHIROUZU K. Effect of surgical stress on endogenous morphine and cytokine levels in the plasma after laparoscopoic or open cholecystectomy. Surg Endosc 2000; 14: 137-140.